Mengfei Guo

1.9k citations
38 papers · 1.1k indexed · h-index 16

Impact in

Papers in

    • Immune cells in cancer 4
    • Immunotherapy and Immune Responses 3

Mengfei Guo

37 papers receiving 1.1k citations

Peers

Mengfei Guo
Comparison fields: 5 of 114
  • Cancer Research 216
  • Immunology 242
  • Oncology 291
  • Pulmonary and Respiratory Medicine 230
  • Molecular Biology 447
Replace Zhilei Lv with:
Zhilei Lv China
Jinshuo Fan China
Carmen C. Diaconu Romania
Breanna M. Allen United States
Tatsuya Nagano Japan
Zaoqu Liu China
Zhigang Chen China
Ping An China
Tony R. Reid United States
Yousef A. Fouad Egypt
Mengfei Guo relative to Zhilei Lv China Zhilei Lv's profile →
Citations per field
00.5×1.7×
Zhilei Lv · 1×
Citations per year

Countries citing papers authored by Mengfei Guo

Since Specialization
Citations

This map shows the geographic impact of Mengfei Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengfei Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengfei Guo more than expected).

Fields of papers citing papers by Mengfei Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengfei Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengfei Guo. The network helps show where Mengfei Guo may publish in the future.

Co-authors

The 25 scholars most cited alongside Mengfei Guo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mengfei Guo Line = papers co-authored together Mengfei Guo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20254
2 20252
3 20254
4 20245
5 202311
6 202315
7 20225
8 202229
9 202185
10 20204
11 202023
12 201936
13 2019185
14 201940
15 201930
16 201840
17 201790
18 201689
19 20159
20 201513

About Mengfei Guo

Mengfei Guo is a scholar working on Aging, Immunology, Oncology, Cancer Research and Toxicology, having authored 38 papers that have together received 1.1k indexed citations. Recurring topics across this work include Extracellular vesicles in disease (10 papers), Nanoplatforms for cancer theranostics (7 papers), Cytokine Signaling Pathways and Interactions (4 papers), Immune cells in cancer (4 papers), Immunotherapy and Immune Responses (3 papers), RNA Interference and Gene Delivery (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Endoplasmic Reticulum Stress and Disease (2 papers). The work is most often cited by research in Cancer Research (216 citations), Immunology (242 citations), Oncology (291 citations), Pulmonary and Respiratory Medicine (230 citations) and Molecular Biology (447 citations). Mengfei Guo has collaborated with scholars based in China, Hong Kong and Belgium. Frequent co-authors include Yang Jin, Feng Wu, Juanjuan Xu, Zhilei Lv, Jinshuo Fan, Guorong Hu, Limin Duan, Jieli Han, Guanghai Yang and Qi Huang. Their work appears in journals such as Frontiers in Immunology, Chemical Engineering Journal, Journal of Extracellular Vesicles, Scientific Reports and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026